James M. Cleary

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

Vasanthi S. Viswanathan, Matthew J. Ryan, Harshil Dhruv et al. · Nature · 2017 · 2K citations · Full text

Medicine, Cancer Biology, Oncology +16

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Surgery +14

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +8